You can also read the IBTA e-News August 2020 edition in full online here.
Some of the highlights from this month's round-up:
- The announcement that the results of the IBTA's survey: 'Brain tumors and COVID-19: the patient and caregiver experience' has been published in the journal Neuro-Oncology Advances. In total, 1,989 participants completed the survey from 33 countries including 1,459 patients and 530 caregivers.
- The 1st Annual Neuro-Oncology Symposium (1ANOS) took place online to launch the Pakistan Society of Neuro-Oncology (PASNO). PASNO is Pakistan’s first scientific society dedicated to neuro-oncology. It brings together experts from within and outside Pakistan to improve the care of patients with tumours of the brain and spinal cord, and provides a platform for research, teaching and training activities related to neuro-oncology in Pakistan.
- Health Canada has approved the use of 5-aminolevulinic acid (5-ALA) and fluorescence guided surgery (FGS) in high grade glioma patients. 5-ALA (Gleolan) is an imaging agent in the form of a powder for oral solution that makes high-grade glioma cells fluoresce under blue light, assisting neurosurgeons to better visualise the tumour and allowing for more complete removal.
- On 23rd September, the European Cancer Organisation launched the European Code of Cancer Practice in the virtual presence of EU Commissioner for Health and Food Safety Stella Kyriakides. The Code is a citizen and patient-centred manifesto of the core requirements for good clinical cancer practice, in order to improve outcomes for all of Europe’s cancer patients. It has been co-produced by a team of cancer patients, patient advocates (including the IBTA’s Chair Kathy Oliver) and cancer healthcare professionals.
- One year after the diagnosis of low-grade glioma, just under three people in ten in Sweden were in full-time employment, according to a study published in Neurology.
- A new report by the Less Survivable Cancers Taskforce – a coalition of six UK-based cancer charities (including The Brain Tumour Charity) – has published a report, Closing the deadly cancer gap: Detect early, Diagnose fast, Save lives, calling on the UK government to take concerted action to ensure that patients with brain, liver, lung, pancreatic, stomach, oesophageal, and pancreatic cancers are diagnosed as early as possible.
- A recent study from Tata Memorial Centre, India, reports the serial outcomes of patient-reported quality of life (QOL) and activities of daily living (ADL) in brain tumour patients has observed largely stable QOL and improved ADL until one year after re-irradiation, supporting the use of re-irradiation as a standard treatment option for recurrent high-grade gliomas.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.